TransCode Therapeutics Pitch Deck (2022): 44-Slide Breakdown

TransCode Therapeutics is a clinical-stage oncology company (NASDAQ: RNAZ) tackling the primary cause of cancer mortality: metastasis. Their presentation centers on a proprietary delivery mechanism designed to overcome the historical challenge of reaching genetic targets outside the liver. The deck highlights their lead candidate, TTX-MC138, which has shown 100% elimination of local metastases in preclinical Triple Negative Breast Cancer (TNBC) models. By positioning RNA therapeutics as the next logical evolution following the success of antibody treatments, TransCode builds a macro-case for…

Key takeaways

• Metastasis is identified as the cause of 90% of cancer deaths, representing a $111 billion market by 2027 (Slide 6).
• The core technical challenge addressed is the efficient delivery of oligonucleotides to organs and tissues other than the liver (Slide 11).
• Lead candidate TTX-MC138 achieved 100% elimination of local metastases and 65% elimination of distant metastases in preclinical models (Slide 21).
• The company is publicly traded on the NASDAQ under the symbol RNAZ (Slide 1).
• TransCode utilizes a RIG-I signaling pathway to trigger immune responses and tumor cell death via their TTX-RIGA candidate (Slide 41).
• A detailed milestone roadmap targets Phase I/II patient dosing in 1H 2023 following IND enabling studies (Slide 31).
• The deck draws a direct parallel between the historical growth of Antibody therapeutics and the current trajectory of RNA therapeutics (Slide 36).
• The pipeline includes diverse candidates for Pancreatic cancer, Osteosarcoma, SCLC, and GBM (Slide 31).

Frequently asked questions

What is the primary problem TransCode Therapeutics is trying to solve?

TransCode is focused on metastatic cancer, which Slide 6 notes is responsible for 90% of all cancer deaths. Specifically, they are addressing the 'delivery challenge' in RNA therapeutics—the difficulty of getting therapeutic oligonucleotides to reach targets beyond the liver, which has historically limited the efficacy of genetic medicines in oncology.

What is the status of their lead therapeutic candidate?

Their lead candidate, TTX-MC138, is moving toward clinical trials. According to the milestone chart on Slide 31, the company planned to complete IND-enabling studies and file an eIND in late 2022, with the goal of dosing patients in Phase I/II trials by the first half of 2023.

How does TransCode justify the market potential of RNA therapeutics?

Slide 36 uses a comparative historical analysis. It maps the development of Antibody (Ab) therapeutics, which grew into a $186B market with over 100 approved drugs, against the timeline of RNA development. They suggest that RNA is currently at a similar 'unlock' point, accelerated by the 2021 approval of mRNA COVID-19 vaccines.

What preclinical evidence is provided for their technology?

Slide 21 presents data from Triple Negative Breast Cancer (TNBC) models. The results show that TTX-MC138 eliminated local metastases (lung and lymph nodes) in 100% of treated animals and distant metastases in 65% of treated animals, with no recurrence or toxicity observed after therapy cessation.

What other indications is TransCode targeting besides breast cancer?

The pipeline and milestone slides (31) show a broad interest in hard-to-treat cancers. This includes preclinical studies for Pancreatic ductal adenocarcinoma (PDAC), Osteosarcoma, Small Cell Lung Cancer (SCLC), and Glioblastoma Multiforme (GBM), as well as an mRNA vaccine program.

TransCode Therapeutics pitch deck: the facts

Company

TransCode Therapeutics

Year

2022

Stage

Public (NASDAQ: RNAZ)

Slides

44

Sector

Biotechnology / Oncology

Deck type

Investor Presentation

Outcome

Publicly Traded

Headquarters

Boston, MA (implied by MIT/Langer references and typical biotech hubs)

TransCode Therapeutics pitch deck PDF

The full TransCode Therapeutics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the TransCode Therapeutics, Inc. pitch deck was used for

This is TransCode Therapeutics’ September 2022 investor presentation, prepared after the company had gone public on the Nasdaq Capital Market under the ticker RNAZ. The deck positions TransCode as an RNA oncology platform company focused on delivering RNA therapeutics to metastatic cancer lesions, with lead candidate TTX‑MC138 targeting microRNA‑10b. In 2022 the company was transitioning from preclinical data into a planned first‑in‑human Phase 0 microdose trial in approximately 12 patients to demonstrate delivery of TTX‑MC138 to metastases and inform subsequent Phase I/II development. The presentation appears intended for public‑market investors ahead of that Phase 0 trial and associated capital needs, rather than a private venture round.

Business model: TransCode Therapeutics is an RNA oncology company developing RNA‑based therapeutics for metastatic cancers using a proprietary nanoparticle delivery platform, with multiple candidates built on the same delivery technology.

Industry

Biotechnology / Oncology, focused on RNA therapeutics for metastatic cancer.

What happened after the TransCode Therapeutics, Inc. deck

Since presenting its September 2022 investor deck, TransCode Therapeutics has moved its lead candidate TTX‑MC138 from planning Phase 0 delivery studies into completed Phase 1a safety and disease‑stabilization trials and has initiated Phase 2a clinical development in metastatic cancer, while remaining listed on Nasdaq under the symbol RNAZ and continuing platform and pipeline work.

• Common stock has traded on the Nasdaq Capital Market under the ticker RNAZ since July 9, 2021, following an IPO of 7,187
• TransCode received FDA guidance via a pre‑IND submission and proceeded to a first‑in‑human study of TTX‑MC138 under expl
• A Phase 0 microdose clinical trial of radiolabeled TTX‑MC138 in patients with advanced metastatic cancer was initiated t
• A Phase 1a clinical trial of TTX‑MC138 in metastatic disease was completed with reported safety and durable disease cont
• By mid‑2026, the company reported initiation of a Phase 2a clinical trial of TTX‑MC138 and continued development across

What the TransCode Therapeutics, Inc. deck got right

• Clear, mechanistically grounded lead asset story. The deck showcases a clearly defined lead program, TTX‑MC138, with a detailed mechanism of action: an iron‑oxide nanocarrier delivering an oligonucleotide that binds and inhibits microRNA‑10b, leading to metastatic tumor cell death and regression. This specificity helps investors understand how the therapy works and why microRNA‑10b is a compelling target in metastasis.
• Compelling preclinical efficacy claims against metastasis. Preclinical data highlighted around TTX‑MC138 report complete regression of established metastases with no recurrence and no observed toxicity in multiple triple‑negative breast cancer models when combined with low‑dose chemotherapy. This creates a strong efficacy narrative at the preclinical stage and supports the deck’s focus on eliminating metastasis rather than merely shrinking tumors.
• Strong articulation of a large, urgent target market. The presentation frames metastatic cancer as responsible for approximately 90% of cancer deaths annually and emphasizes that TTX‑MC138 could be applicable across many tumor types, including breast, pancreatic, ovarian, colon cancer, and glioblastoma, among others. This high‑level market framing ties the scientific story to a large, clinically urgent opportunity.
• Well‑defined initial clinical trial as a near‑term catalyst. The deck includes a concrete near‑term clinical plan: a 12‑patient Phase 0 microdose trial using radiolabeled TTX‑MC138 to demonstrate delivery to radiographically confirmed metastases, including extra‑hepatic sites. This gives investors a clear upcoming milestone and path to de‑risk the platform’s core delivery hypothesis.
• Platform breadth with multiple RNA oncology programs. Beyond TTX‑MC138, the company’s materials and the 2022 investor presentation reference a diversified pipeline — TTX‑siPDL1, TTX‑siLIN28b, TTX‑RIGA, TTX‑CRISPR, TTX‑mRNA — all built on the same delivery platform. This breadth supports a platform valuation thesis and indicates that the technology could be extended to multiple mechanisms and indications.
• Public‑market status providing transparency and access to capital. The deck is anchored in the context of a company already trading publicly on Nasdaq under the ticker RNAZ, with prior IPO details disclosed in SEC filings. This public‑market footing can increase transparency around governance, disclosure, and access to capital compared with an earlier‑stage private biotech.

What could have been stronger

• Limited explicit fundraising and runway detail in the deck. The September 2022 deck is centered on scientific rationale and planned clinical design but does not clearly connect these elements to a specific capital raise amount, use of proceeds breakdown, or expected cash runway, which can make it harder for public‑market investors to evaluate financing risk versus the development plan.
• Heavy reliance on preclinical data at the time of the deck. While preclinical data on TTX‑MC138 describe complete regression of metastases with no recurrence and no toxicity in animal models, the deck sits at a point where no human efficacy data were yet available; later sources confirm that initial trials were microdose Phase 0/1a studies focused on delivery and safety rather than tumor response. For a 2022 investor audience, this means the investment case relied heavily on preclinical results and mechanistic rationale, with limited de‑risking from human data.
• High‑level market framing without detailed competitive and indication analysis. Company materials emphasize the size of the metastatic cancer burden (around 90% of cancer deaths) and a potential multi‑indication reach, but public documents do not show that the 2022 deck provided granular indication‑level market sizing, competitive landscape versus other RNA or anti‑metastatic therapies, or explicit positioning versus standard of care in each target cancer.
• Limited visibility into timelines and prioritization for non‑lead pipeline assets. Although the deck and related materials describe a robust pipeline (TTX‑siPDL1, TTX‑siLIN28b, TTX‑RIGA, TTX‑CRISPR, TTX‑mRNA), there is limited detail on development stage, timelines, or resource allocation for these programs in the 2022 investor presentation, leaving investors with an incomplete view of how and when the platform beyond TTX‑MC138 might generate value.

How an investor would read this deck

What draws attention

• Evidence that the iron‑oxide nanoparticle platform can reliably deliver nucleic‑acid therapeutics such as TTX‑MC138 to metastatic lesions in humans, beyond preclinical models.
• The transition from Phase 0/1a delivery and safety studies to Phase 2a efficacy trials, including trial design, endpoints, and patient selection (for example ctDNA‑positive colorectal cancer after curative‑intent therapy).
• Regulatory interactions and milestones, including IND status, FDA feedback, and any special designations, given the first‑in‑class nature of a microRNA‑10b‑targeting anti‑metastatic therapy.
• Financing strategy and dilution: prior IPO details and subsequent underwritten public offerings, together with planned cash runway and capital needs through key clinical inflection points.
• Development of the broader RNA oncology pipeline beyond TTX‑MC138 and whether the platform can be validated across additional targets such as PD‑L1, LIN28b, innate immune agonists, CRISPR, and mRNA.

Risks that stand out

• TTX‑MC138 and the broader pipeline are early‑stage; initial human studies were microdose and early‑phase trials focused on delivery and safety, so there is still substantial uncertainty about clinical efficacy in metastatic cancer.
• The therapeutic strategy depends on reliably targeting and inhibiting microRNA‑10b in metastatic cells; if target expression, delivery, or binding is heterogeneous across tumors or patients, clinical benefit could be limited.
• The FDA has not evaluated or approved TTX‑MC138, and regulatory pathways for first‑in‑class RNA therapeutics targeting microRNAs in metastasis may present unforeseen hurdles.
• The company is publicly listed and has used underwritten offerings to raise capital; additional financing may be needed to fund Phase 2a and later‑stage trials, potentially leading to dilution if not offset by strong clinical data or partnerships.
• Execution risk exists in scaling manufacturing of iron‑oxide nanoparticle conjugates, ensuring consistent quality and safety, and managing the complexity of multiple RNA modalities (siRNA, CRISPR, mRNA) on the same platform.

Questions this deck invites

• What were the exact design, inclusion criteria, and endpoints of the planned 12‑patient Phase 0 TTX‑MC138 trial described in the September 2022 deck, and how do they link to the later Phase 1a and Phase 2a programs?
• How does TransCode’s nanoparticle delivery platform compare, in terms of biodistribution, off‑target effects, and manufacturability, with other RNA delivery approaches used in oncology (e.g., lipid nanoparticles, conjugates)?
• What are the detailed results from Phase 0 and Phase 1a trials for TTX‑MC138, including quantitative measures of target engagement, safety, and any signals of disease stabilization or regression across different tumor types?
• What is the company’s current cash position, burn rate, and anticipated financing strategy, including any follow‑on offerings or partnerships since the IPO and 2022 presentation?
• For each pipeline asset (TTX‑siPDL1, TTX‑siLIN28b, TTX‑RIGA, TTX‑CRISPR, TTX‑mRNA), what is the development stage, preclinical evidence, and projected timeline to first‑in‑human studies, and how are resources prioritized among them?

What founders can take from the TransCode Therapeutics, Inc. deck

• A scientifically dense deck for a public biotech can credibly anchor around a single clear lead asset — in this case TTX‑MC138 targeting microRNA‑10b — while still signaling a broader platform through concise mentions of additional RNA programs.
• Positioning around a large, well‑defined problem such as metastatic cancer (responsible for the majority of cancer deaths) can help investors quickly grasp the significance of a therapeutic platform, even before human efficacy data are available.
• Describing a concrete near‑term clinical milestone, such as a 12‑patient Phase 0 microdose trial to demonstrate drug delivery to metastases, provides a tangible catalyst that connects preclinical data to an investable timeline.
• Clear articulation of mechanism of action — nanoparticle uptake by metastatic cells, binding to microRNA‑10b, and subsequent cell death and disease regression — can make complex RNA therapeutics more accessible to generalist public‑market investors.
• Including a pipeline overview with programs like TTX‑siPDL1, TTX‑siLIN28b, TTX‑RIGA, TTX‑CRISPR, and TTX‑mRNA shows how a delivery platform can be extended across multiple cancer targets, which can support a broader investment thesis beyond a single drug.
• Anchoring claims in preclinical results (complete regression of metastases without recurrence and no toxicity in animal models) while clearly noting that the FDA has not yet evaluated or approved the drug helps manage expectations and maintain regulatory transparency.

TransCode Therapeutics, Inc. pitch deck: common questions

What does TransCode Therapeutics do?

TransCode Therapeutics is an RNA oncology company developing therapeutics for metastatic cancer using a proprietary iron‑oxide nanoparticle platform to deliver nucleic‑acid drugs such as antagomirs, siRNA, CRISPR, and mRNA. Its lead candidate, TTX‑MC138, is designed to inhibit microRNA‑10b, a well‑documented driver of metastasis, with the goal of eliminating metastatic disease across multiple tumor types.

What is TTX‑MC138 and what evidence supports it?

TransCode’s lead candidate is TTX‑MC138, an iron‑oxide nanocarrier conjugated to an oligonucleotide that inhibits microRNA‑10b. Preclinical models of triple‑negative breast cancer reported complete regression of established metastases with no recurrence and no observed toxicity when combined with low‑dose chemotherapy, and durable disease control across multiple models. As of 2022–2023, the company planned and then initiated a Phase 0 microdose trial to demonstrate delivery of radiolabeled TTX‑MC138 to metastatic lesions in patients with advanced solid tumors.

What clinical and pipeline plans are described in the 2022 deck?

The September 2022 investor presentation focuses on the planned Phase 0 clinical trial of TTX‑MC138 in approximately 12 patients with advanced metastatic cancer, aiming to show that the radiolabeled drug reaches metastatic lesions, including those outside the liver. The deck also outlines the broader pipeline, which includes candidates such as TTX‑siPDL1, TTX‑siLIN28b, TTX‑RIGA, TTX‑CRISPR, and TTX‑mRNA, each leveraging the same RNA delivery platform to target different cancer mechanisms.

What is TransCode Therapeutics’ stock market status and prior fundraising?

TransCode completed an IPO prior to this deck; its common stock has traded on the Nasdaq Capital Market under the symbol RNAZ since July 9, 2021, at an initial public offering price of $4.00 per share for 7,187,500 shares, including the underwriter’s overallotment option. Later, the company announced additional underwritten public offerings of common stock, but public information does not clearly tie a specific follow‑on offering directly to the September 2022 presentation.

What are the main risks associated with TransCode’s program as of and after the 2022 deck?

The primary risk factors highlighted across company materials include the early‑stage nature of TTX‑MC138 (initially preclinical, then Phase 0/1a), the fact that the FDA has not yet approved the product, and uncertainties around translating preclinical regression of metastases into clinical benefit. As of later updates, while Phase 1a data suggested safety and disease stabilization, efficacy must still be demonstrated in planned Phase 2a trials for specific indications such as ctDNA‑positive colorectal cancer.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• TTX-MC138 - Old - TRANSCODE THERAPEUTICS, INC.
• TransCode Therapeutics Successfully Completes Phase 1a Clinical...
• TransCode Therapeutics Announces Preliminary Clinical Results in...
• TRANSCODE THERAPEUTICS, INC. - Home
• Lead Candidate - TTX-MC138 - transcode therapeutics, inc.
• [PDF] TTX-MC138 - transcode therapeutics, inc.
• TransCode Therapeutics Announces Publication of Preclinical Data...
• Trans Code Therapeutics Investor Presentation 2022 | PDF

TransCode Therapeutics pitch deck slides

What each slide of the TransCode Therapeutics pitch deck says

Slide 2

ons Disclaimer Forward Looking Statements & a : CO Statements in this presentation contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding TransCode Therapeutics, Inc.'s expectations regarding projected timelines of clinical trials, and expectations regarding current or future clinical trials. Forward-looking statements are based on TransCode Therapeutics, Inc’s current e…

Slide 3

aid Corporate Capitalization E ST Source of Capital Amount NASDAQ Symbol: RNAZ Seed Capital (Angel investors) $2,240,000 Common Shares 12,977,234 SBIR Grant 2,300,000 | | Options (WAEP $0.77) 2,094,033 IPO (Net Proceeds) 25,400,000 Underwriter Warrants (WAEP $5.00) 312,500 Total $29,940,000 Total 15,383,767 + Insider ownership (fully diluted): 39% = Cash at June 30, 2022 (including expected SBIR receipts): $15.4M * Approximate monthly cash burn (first half 2022): $1.3M

Slide 4

oR ~ — Rapidly advancing new scientific discoveries to revolutionize the way cancer is treated

Slide 5

nS oF ae Market Competitive Landscape — Top 5 Cancer Drugs (2021 Revenue”) - : Despite considerable advancement in the - field of cancer therapy, cancer remains the Keytruda (Merck) $17.18 Billion leading cause of death worldwide. The global top selling cancer drug market Revlimid (Bristol Myers) $12.8 Billion growth is driven by rise in the incidence of cancer, growing healthcare expenditures, ) and improved infrastructure for drug Opdivo (Bristol Myers) S$ 7.5 Billion development. Additionally, growing awareness regarding Ibrance (Pfizer) $ 5.4 Billion early diagnosis and treatment has directed the anticancer drug market to grow at significant rate. Imbruvica (Abbvie) $ 5.4 Billion * http…

Slide 6

Problem Critical Need for Therapy Targeting Metastasis - T J Metastatic Cancer Reduces 5-year Survival Critical Need for Therapy Targeting Metastasis” 90% S111 8B of Cancer Global Metastatic Deaths Due Cancer Treatment to Metastasis Market by 2027

Slide text above is read directly from the TransCode Therapeutics deck PDF embedded on this page.

Related fundraising guides (24)

• Hintsa Pitch Deck Teardown: A $5.2M Masterclass in High-Performance Wellness Branding
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Thematic Pitch Deck Teardown: Leveraging Creator Networks for Scalable Music Promotion
• Here Pitch Deck Teardown: A $5M Seed Round for Fractional Vacation Rental Ownership
• Covey Pitch Deck Teardown: Decentralizing Asset Management via Immutable Track Records
• Arize AI Pitch Deck Teardown: A Masterclass in Category Creation and Market Timing
• RegioHelden Pitch Deck Teardown: A Masterclass in Local Marketing Unit Economics
• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation
• micro1 Pitch Deck Teardown: Leveraging Growth Momentum and AI Vetting for Global Engineering
• Fictiv Pitch Deck Teardown: A $100M Series E Masterclass in Supply Chain Simplification
• Cellarity Pitch Deck Teardown: A $121M Series C Masterclass in Platform-First Biotech
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Impossible Kicks Pitch Deck Teardown: Scaling High-Volume Physical Retail for Sneaker Resale

Decks from the same year (1)

• 2022 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with T

More pitch deck teardowns (16)

• Trailer Dynamics Pitch Deck Teardown: Engineering a Smart Electric Drivetrain for Logistics
• TrainCan At Amore Paradise Pitch Deck Teardown: A High-Stakes Luxury Matchmaking Vision
• Trala Pitch Deck Teardown: Scaling Music Education via Signal Processing and Live Lessons
• TransactionLink Pitch Deck Teardown: A 10-Slide Masterclass in Fintech Automation Efficiency
• Transcarent Pitch Deck Breakdown: A Masterclass in Category Creation and Enterprise Scale
• Transcend Pitch Deck Breakdown: Automating the $9 Trillion Infrastructure Design Gap
• Transcend Pitch Deck Teardown: A $20M Series B Masterclass in Vertical SaaS Expansion
• Trans Code Therapeutics Pitch Deck Teardown: Solving the RNA Delivery Challenge in Oncology
• TransferWise Pitch Deck Teardown: How a 4-Step Process Slide Anchored a Billion-Dollar Vision
• TransferWise (Wise) Pitch Deck Breakdown
• TranslateKarate Pitch Deck Teardown: A Minimalist Approach to Localization Workflow
• Transtutors Pitch Deck Breakdown: A 2007 Relic of the Early EdTech Outsourcing Era
• Trash Warrior Pitch Deck Breakdown: Disrupting the $56B Commercial Waste Market
• Travacco Pitch Deck Teardown: Targeting Emerging Market Travel Agencies with Niche ERP
• Travel Lisa Pitch Deck Teardown: A Lean Chatbot Play Focused on API Monetization
• TravelPerk Pitch Deck Breakdown: A Product-First Narrative for Later-Stage Growth

Recently published pitch deck teardowns (12)

• Heyday Pitch Deck Breakdown: A $2M Seed Round for Conversational AI in Retail
• Iconfinder Pitch Deck Breakdown: Scaling a Search Engine into a Global Marketplace
• iControl Pitch Deck Breakdown: High-Velocity Traction in Construction Tech
• Ibble Pitch Deck Breakdown: A $12.7M Seed Bet on Asynchronous Video Conversations
• Illumen Capital Pitch Deck Breakdown: A $168M Fund of Funds Strategy for Bias Reduction
• iGrow Pitch Deck Breakdown: Scaling Indonesian AgTech Through Fractional Investment
• iFarm Pitch Deck Breakdown: A $4M Seed Round Built on Automated Vertical Farming
• Immo Pitch Deck Breakdown: Institutionalizing European Residential Real Estate
• Indemand Pitch Deck Breakdown: A Minimalist Approach to On-Demand SaaS
• Island Pitch Deck Breakdown: A $115M Series B Masterclass in Category Creation
• 4rented Pitch Deck Teardown: A Minimalist Look at a Pre-Product Rental Marketplace
• 1847 Holdings Pitch Deck Teardown: A Public Approach to Micro-Cap Private Equity

Fundraising library · Pitch deck examples · Investor directory · Founder database